Drug Trial Radar · NCT07515209
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Dec 20, 2024
Primary completion
Dec 15, 2025
Study completion Dec 15, 2025
Sponsor
- Lead sponsor
- Huahui HealthIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of HH-006 in untreated chronic HBV patients. Each cohort includes 12 participants (9 active, 3 placebo), with dose progression approved by a Safety Review Committee. Participants are monitored through 24 weeks post-dose. The study design allows for adjustments based on emerging data.
Conditions
- Chronic Hepatitis B Virus Infection
Interventions
HH-006Biological
120 mg, 240 mg, 480 mg subcutaneous QW, 5 doses
0.9% normal salineDrug
1 mL, 2 mL, 4 mL subcutaneous QW, 5 doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: up to 24 weeks follow-up
- Clinically significant abnormalitiesTime frame: up to 24 weeks follow-up
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The Affiliated Panyu Central Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The Eighth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.